Rein Therapeutics Stock Performance
| RNTX Stock | 1.55 0.17 12.32% |
The company holds a Beta of 0.56, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Rein Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Rein Therapeutics is expected to be smaller as well. At this point, Rein Therapeutics has a negative expected return of -0.23%. Please make sure to check Rein Therapeutics' maximum drawdown, daily balance of power, relative strength index, as well as the relationship between the skewness and day typical price , to decide if Rein Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Rein Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in August 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 17.3 M |
Rein Therapeutics Relative Risk vs. Return Landscape
If you would invest 191.00 in Rein Therapeutics on April 25, 2025 and sell it today you would lose (36.00) from holding Rein Therapeutics or give up 18.85% of portfolio value over 90 days. Rein Therapeutics is currently does not generate positive expected returns and assumes 4.8955% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Rein, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rein Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rein Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Rein Therapeutics, and traders can use it to determine the average amount a Rein Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0462
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RNTX |
Estimated Market Risk
| 4.9 actual daily | 43 57% of assets are more volatile |
Expected Return
| -0.23 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Rein Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rein Therapeutics by adding Rein Therapeutics to a well-diversified portfolio.
Rein Therapeutics Fundamentals Growth
Rein Stock prices reflect investors' perceptions of the future prospects and financial health of Rein Therapeutics, and Rein Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rein Stock performance.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.32 | ||||
| Current Valuation | 35.6 M | ||||
| Shares Outstanding | 21.67 M | ||||
| Price To Book | 1.05 X | ||||
| EBITDA | (28.05 M) | ||||
| Total Debt | 7.8 M | ||||
| Book Value Per Share | 2.32 X | ||||
| Cash Flow From Operations | (22.29 M) | ||||
| Earnings Per Share | (2.88) X | ||||
| Total Asset | 62.19 M | ||||
| Retained Earnings | (351.4 M) | ||||
About Rein Therapeutics Performance
Evaluating Rein Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Rein Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Rein Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Rein Therapeutics performance evaluation
Checking the ongoing alerts about Rein Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Rein Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rein Therapeutics generated a negative expected return over the last 90 days | |
| Rein Therapeutics may become a speculative penny stock | |
| Rein Therapeutics has high historical volatility and very poor performance | |
| Rein Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Rein Therapeutics was previously known as ALRN Old and was traded on NASDAQ Exchange under the symbol ALRN. | |
| Net Loss for the year was (62.88 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rein Therapeutics generates negative cash flow from operations |
- Analyzing Rein Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rein Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Rein Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rein Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rein Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rein Therapeutics' stock. These opinions can provide insight into Rein Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Rein Stock Analysis
When running Rein Therapeutics' price analysis, check to measure Rein Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rein Therapeutics is operating at the current time. Most of Rein Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rein Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rein Therapeutics' price. Additionally, you may evaluate how the addition of Rein Therapeutics to your portfolios can decrease your overall portfolio volatility.